The present systematic review and meta-analysis suggested that the presence of concurrent TP53 mutations predicts a decreased clinical efficacy of EGFR-TKIs and ALK-TKIs and is a negative prognostic factor for patients with advanced NSCLC harboring EGFR sensitive mutations or ALK re-arrangements (regardless of pathological subtype and line of treatments). Here, ALK is linked to non-small cell lung carcinoma.